SCOLR Pha Form 4 December 0'						
FORM	ΙΛ		OMB APPROVAL			
	UNITED STAT	ES SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION OMB Number: 3235-0287			
Check th if no long subject to Section 1 Form 4 c	STATEMENT (OF CHANGES IN BENEFICIAL OV SECURITIES	NERSHIP OF Expires: January 31, 2005 Estimated average burden hours per response 0.5			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						
(Print or Type I	Responses)					
	Address of Reporting Person <u>*</u> MICHAEL N	2. Issuer Name and Ticker or Trading Symbol SCOLR Pharma, Inc. [DDD]	5. Relationship of Reporting Person(s) to Issuer			
			(Check all applicable)			
(Last) 3625 132NI 400	(First) (Middle) O AVENUE SE SUITE	3. Date of Earliest Transaction (Month/Day/Year) 12/07/2007	X_ Director 10% Owner Officer (give title Other (specify below) below)			
	(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check			
BELLEVU	E, WA 98006	Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Table I - Non-Derivative Securities A	quired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date 2A. De (Month/Day/Year) Execu any (Mont	eemed 3. 4. Securities Acquired	5. Amount of Securities 6. Ownership 7. Nature of Form: Direct Indirect Beneficially (D) or Beneficial Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported Transaction(s) (Instr. 3 and 4)			
Common Stock	12/07/2007	P 10,000 A \$ 1.32	438,285 D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SCOLR Pharma, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. tionNumber of) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	3	Date	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code N	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
TAGLICH MICHAEL N 3625 132ND AVENUE SE SUITE 400 BELLEVUE, WA 98006	Х					
Signatures						
Michael N. Taglich by Alan M. Mitchel, Attorney-in-Fact			12/07/20)07		
<u>**</u> Signature of Reporting Person			Date			
Explanation of Responses:						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.